Zilucoplan

(Zilbrysq®)

Zilbrysq®

Latest News

loading GIF

Drug updated on 4/16/2024

Dosage FormInjection (subcutaneous; 16.6 mg/0.416 mL, 23 mg/0.574 mL, 32.4 mg/0.81 mL in single-dose prefilled syringes)
Drug ClassComplement inhibitors
Ongoing and
Completed Studies
ClinicalTrials.gov

Indication

  • Indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive.

Summary
This AI-generated content is provided without warranty and may be inaccurate or outdated; it should be used only as a research starting point, with no liability accepted for reliance on it. Learn more.

  • Zilucoplan (Zilbrysq) is utilized for the management of generalized myasthenia gravis (gMG) in adult patients who are antiacetylcholine receptor (AChR) antibody positive. It demonstrates effectiveness in reducing the quantitative myasthenia gravis score (QMGS), showcasing its role in enhancing clinical results for patients with gMG.
  • The information stems from three systematic reviews/meta-analyses, highlighting Zilucoplan alongside other novel therapies in the context of generalized myasthenia gravis treatment.
  • In a comparison of efficacy and ranking, Zilucoplan is positioned third after batoclimab and eculizumab based on its capacity to decrease QMGS. Conversely, drugs like nipocalimab have shown lower efficacy.
  • In assessing the safety profile, Zilucoplan displayed no significant difference from placebo regarding adverse events. However, it is associated with a lower incidence of adverse events compared to some treatments, with batoclimab leading in safety among the assessed options.
  • Subgroup considerations and population types indicate a variable response to therapy, which could guide personalized treatment strategies based on individual patient factors, for example, prior thymectomy.
  • The documents collectively underscore the necessity for more thorough studies to examine the long-term effects and safety profiles, including that of Zilucoplan, due to wide credible intervals (CrIs) and variability noted among different studies.